Optimal balance of efficacy and tolerability of oral triptans and telcagepant: A review and a clinical comment

Journal of Headache and Pain

Volumn 12, Issue 3, 2011, Pages 275-280

  Tfelt Hansen, Peer ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acute treatment; Dose response curve; Migraine; Telcagepant; Triptans

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TELCAGEPANT; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ANALGESIA; ASTHENIA; CHEST TIGHTNESS; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HUMAN; MEDLINE; META ANALYSIS (TOPIC); MIGRAINE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SOMNOLENCE; THORAX PAIN; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

AZEPINES; HUMANS; IMIDAZOLES; MIGRAINE DISORDERS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SEROTONIN 5-HT1 RECEPTOR AGONISTS; TRYPTAMINES;

EID: 79958105758     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-011-0309-5     Document Type: Review

References (34)

1. The Subcutaneous Sumatriptan International Study Group 1991 Treament of migraine attacks with sumatriptan N Eng J Med 325 316 321 10.1056/ NEJM199108013250504
2. RK Cady JK Wendt JR Kirchner JD Sargent JF Rothrock H Skaggs Jr 1991 Treatment of acute migraine with subcutaneous sumtriptan JAMA 265 2831 2835 1851894 10.1001/jama.265.21.2831 1:STN:280:DyaK3M3jsl2ntw%3D%3D
3. C Dahlöf L Hogenhuis J Olesen H Petit J Ribbat J Schoenen, et al. 1998 Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study Eur J Neurol 5 469 477 10210876 10.1046/j.1468-1331.1998.550469.x (Pubitemid 28470001)
4. P Tfelt-Hansen 2007 Parenteral versus oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment J Headache Pain 8 273 276 17955173 10.1007/s10194-007-0411-x 1:CAS:528:DC%2BD1cXitlGktrs%3D (Pubitemid 350214724)
5. Olesen J, Goadsby PJ, Ramadan N, Tfelt-Hansen P, Welch KMA (2006) The Headaches, 3rd edn edn. Lippincott Williams and Wilkins, Philadelphia, pp 1-1169
6. V Pfaffenrath G Cunin G Sjonell S Pendergast 1998 Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan Headache 38 184 190 9563208 10.1046/j.1526-4610.1998.3803184.x 1:STN:280:DyaK1c3isVeisA%3D%3D (Pubitemid 28173759)
7. P Tfelt-Hansen J Teall F Rodriguez M Giacovazzo J Paz W Malbecq GA Block SA Reines WH Visser 1998 Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 study Group Headache 38 748 755 11284463 10.1046/j.1526-4610.1998.3810748.x 1:STN:280:DC%2BD3M3js1eiug%3D%3D (Pubitemid 29031071)
8. F Sheftell R Ryan V Pitman Eletriptan Steering Committee 2003 Efficacy, safety and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States Headache 43 202 213 12603638 10.1046/j.1526-4610.2003.03043.x (Pubitemid 36348766)
9. R Stark C Dahlöf S Haughie J Hettiarchchi Eletriptan Steering Committee 2002 Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks Cephalalgia 22 23 32 11993610 10.1046/j.1468-2982. 2002.00300.x 1:STN:280:DC%2BD383ltlGrsA%3D%3D (Pubitemid 34626021)
10. H Gijsmant MS Kramer J Sargent M Tuchman D Maczura-Wolfe A Polis, et al. 1997 Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine Cephalalgia 17 647 651 10.1046/j.1468-2982.1997.1706647.x (Pubitemid 27448672)
11. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari Md (1996) Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Arch Neurol 53:1132-1137 (Pubitemid 26380294)
12. Sumatriptan-an oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group (1991) Eur Neurol 31: 300-305
13. MD Ferrari KI Roon RB Lipton PJ Goadsby 2001 Oral triptans (serotonin 5-HT (1B/1D) agonists in the acute migraine treatment: a metaanalysis of 53 triptans Lancet 358 1668 1675 11728541 10.1016/S0140-6736(01)06711-3 1:CAS:528:DC%2BD3MXos1ajsro%3D (Pubitemid 33124324)
14. AM Rapoport NM Ramadan JU Adelman NT Mathew AH Elkind DB Kudrow, et al. 1997 Optimizing the dose of zolmiriptan (Zomig, 311C90) for the acue reatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study Neurology 49 1210 1218 9371896 1:CAS:528:DyaK2sXnslylsrY%3D
15. Saxena PR, Tfelt-Hansen P (2006) Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The Headaches, 3rd edn edn. Lippincott Williams and Wilkins, Philadelphia, pp 469-503
16. H Havanka C Dahlöf PH Pop HC Diener P Winter H Whitehouse, et al. 2000 Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group Clin Ther 22 970 980 10972633 10.1016/S0149-2918(00)80068-5 1:CAS:528:DC%2BD3cXmsFSqtLw%3D
17. Salonen R (2001) Naratripan: the gentle triptan. In: Humphrey P, Ferrari M, Olesen J (eds) The triptans: novel drugs for migraine. Oxford University Press, Oxford, pp 228-235
18. C Dahlöf P Tfelt-Hansen H Massiou A Fazekas Almotriptan Study Group 2001 Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine Neurology 57 1811 1817 11723269 (Pubitemid 33096688)
19. A Rapoport R Ryan J Goldstein C Keywood 2002 Dose range-finding studies with frovatriptan in the acute treatment of migraine Headache 42 Suppl 2 S74 S83 12028323 10.1046/j.1526-4610.42.s2.5.x
20. TW Ho LK Mannix X Fan C Assaid C Furtek CJ Jones, et al. 2008 Randomized controlled trial pf an oral CGRP receptor antagonist. MK-0974, in acute treatment of migraine Neurology 70 1304 1312 17914062 10.1212/01.WNL.0000286940. 29755.61 1:CAS:528:DC%2BD1cXktlOhtLs%3D (Pubitemid 351550355)
21. KM Connor RE Shapiro H-C Diener S Lucas J Kost X Fan, et al. 2009 Randomized, controlled trial of telcagepant for the acute treatment of migraine Neurology 73 970 977 19770473 10.1212/WNL.0b013e3181b87942 1:CAS:528: DC%2BD1MXhtFantLfE
22. KA Petersen S Birk LH Lassen C Kruuse O Jonassen L Lesko J Olesen 2005 The CGRP-antagonist BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers Cephalalgia 25 139 147 15658951 10.1111/j.1468-2982.2004.00830.x 1:STN:280:DC%2BD2M%2Fjt1Kktw%3D%3D (Pubitemid 40193957)
23. TW Ho MD Ferrari DW Dodick J Galet J Kost X Fan, et al. 2008 Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomized, placebo-controlled, parallel-treatment trial Lancet 372 2115 2123 19036425 10.1016/S0140-6736(08)61626-8 1:CAS:528:DC%2BD1cXhsFajs7nE
24. PJ Goadsby 2002 New directions in migraine research J Clin Neurosci 9 368 373 12217664 10.1054/jocn.2001.0967
25. P Tfelt-Hansen NH Bjarnason CGH Dahlöf S Derry E Loder H Massiou Task Force on Adverse Events in Migraine Trials of the Subcommittee on Clinical Trials of the International Headache Society 2008 Evaluation and registration of adverse events in clinical drug trials in migraine Cephalalgia 28 683 688 18498392 10.1111/j.1468-2982.2008.01600.x 1:STN:280:DC%2BD1cznvVartA%3D%3D (Pubitemid 351799757)
26. PJ Goadsby D Dodick M Almas H-C Diener P Tfelt-Hansen RB Lipton B Parsson 2007 Treatment emergent CNS symptoms following triptan therapy are part of the migraine attack Cephalalgia 27 254 262 17381558 10.1111/j.1468-2982.2007.01278.x 1:STN:280:DC%2BD2s7otFKgtg%3D%3D (Pubitemid 46354126)
27. Tfelt-Hansen P, Saxena PR (2006) Ergot alkaloids in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The Headaches, 3rd edn edn. Lippincott Williams and Wilkins, Philadelphia, pp 459-467
28. P Tfelt-Hansen 2009 Unpublished sumatriptan clinical trials Lancet 374 1501 1502 19880018 10.1016/S0140-6736(09)61906-1
29. P Tfelt-Hansen 2011 Excellent tolerability but relatively low initial efficacy of the oral CGRP antagonist telcagepant in the treatment of migraine Headache 51 118 123 21070229 10.1111/j.1526-4610.2010.01797.x
30. J Pascual V Mateos C Roig M Sanchez-Del-Rio D Jiménez 2007 Marketed triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability Headache 47 1152 1168 17883520 10.1111/j.1526-4610. 2007.00849.x (Pubitemid 47457766)
31. P Tfelt-Hansen L Edvinsson 2007 Pharmacokinetic and pharmacodynamic variability as possible causes for different drug responses in migraine. A comment Cephalalgia 232.7 1091 1093 10.1111/j.1468-2982.2007.01372.x (Pubitemid 47476131)
32. NT Mathew 1997 Serotonin1D (5-HT1D) agonists and other agents in acute migraine Neurol Clin 15 61 83 9058397 10.1016/S0733-8619(05)70295-4 1:STN:280:DyaK2s3htFequw%3D%3D (Pubitemid 27098700)
33. JG Edmeads DS Millson 1997 Tolerability profile of zolmitriptan (ZomigTM, 311C90, a novel dual central and peripherally acting 5HT1B/1D agonist. International experiemce based on >3000 subjects treated with zolmitriptan Cephalalgia 17 41 52 9399016
34. CG Dahlöf J Saiers 1998 Sumatriptan injection and tablets in clinical practice: results of a survey of 707 migraineuers Headache 38 756 763 11279901 10.1046/j.1526-4610.1998.3810756.x (Pubitemid 29031072)